| |
The BD FACSymphony A5 SE Cell Analyzer adds high-sensitivity detectors to detect the full spectrum of emitted light. Unmix spectral data live, all while retaining the flexibility of familiar compensation-based workflows. Learn more. 
|
|
Today's Big NewsNov 11, 2022 |
| By Nick Paul Taylor Deep into the fall season, biotechs are freeing themselves of dead wood at a rapid pace. The latest batch of quarterly updates saw Atreca, aTyr Pharma, Histogen, Lisata Therapeutics, Poseida Therapeutics and Rain Therapeutics trim their pipelines. |
|
|
|
By James Waldron Irish biotech Nabriva Therapeutics has responded to the tough financial climate by putting all its chips on the approved bacterial skin medicine Sivextro, meaning that its R&D projects and 40% of staff are now surplus to requirements. |
By Nick Paul Taylor Moderna has struck another deal with an antibody specialist, paying Nona Biosciences $6 million upfront and committing up to $500 million in milestones for access to the fruits of a heavy chain only discovery platform. |
By Max Bayer New charges from the SEC allege that an insider trading scheme related to Merck & Co.'s acquisition of Pandion was a family affair. The brother of one of the two men first charged in July was also tipped off about the deal, the agency has alleged. |
By Gabrielle Masson Tiziana Life Sciences is following biotech’s third-quarter cull trend, though it’s attempting to do so more covertly by putting several of its pipeline programs on the shelf in a “near-term focus” strategic update. |
By Helen Floersh Thanks to the right mix of science and serendipity, researchers found that mutations in the promoter regions of a pair of genes are key to creating the extra-long telomeres that turn skin cells into cancer. |
By Teresa Carey This week on “The Top Line,” we share some highlights from Fierce Biotech's Cell and Gene Therapy Forum in case you missed it. |
By Gabrielle Masson,Max Bayer After a tumultuous few months for Seagen, the company has tapped former Novartis Pharmaceuticals CEO David Epstein to lead. |
By Kevin Dunleavy How did investors receive news of Biogen’s hire of Christopher Viehbacher as the company’s CEO? The reaction is decidedly mixed, with lots of strong opinions on both sides, according to an anonymous survey conducted by Mizuho Securities. |
By Frank Diamond Nurses feel that Kaiser Permanente doesn’t do enough to ease the burdens brought on partly by COVID-19. So, they’re going on strike for three days. |
By Ben Adams Eli Lilly has become the first Big Pharma to fall victim to the uptick of fake Twitter handles that are cropping up under the new Twitter Blue paid accounts that Elon Musk recently pushed through. A user pretending to be the Indianapolis company tweeted out a message saying: “We are excited to announced insulin is free now.” |
By Anastassia Gliadkovskaya As preventive care remains out of reach for millions, several companies are harnessing technology to support the in-home care model while also enabling virtual primary care. |
By Angus Liu The CEOs of BioNTech, Bayer and Merck KGaA visited China as part of German Chancellor Olaf Scholz's business delegation. Insilico Medicine became the latest AI drug discovery shop to partner with Sanofi. Sumitomo Pharma is launching a round of layoffs in Massachusetts. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we share some highlights from Fierce Biotech's Cell and Gene Therapy Forum in case you missed it. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
